Viridian Therapeutics, Inc.\DE (VRDN) Net Cash Flow (2013 - 2026)

Viridian Therapeutics, Inc.\DE's Net Cash Flow history runs 14 years deep, the most recent figure standing at -$36.0 million for Q1 2026.

• On a quarterly basis, Net Cash Flow fell 316.81% year-over-year to -$36.0 million in Q1 2026; TTM through Mar 2026 was $60.1 million, a 144.69% increase from a year earlier, with the FY2025 full-year figure at $112.8 million, up 3588.65% from the prior year.
• Net Cash Flow retreated to -$36.0 million in Q1 2026 per VRDN's latest filing, from $42.7 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $312.9 million in Q3 2022 and bottomed at -$188.6 million in Q4 2022.
• The 5-year median for Net Cash Flow is $435000.0 (2022), against an average of $7.9 million.
• Across the five-year window, Net Cash Flow tumbled 2032.6% in 2022 and soared 1218.35% in 2024, its largest moves.
• Year by year, Net Cash Flow stood at -$188.6 million in 2022, then surged by 95.35% to -$8.8 million in 2023, then sank by 1048.49% to -$100.7 million in 2024, then soared by 142.43% to $42.7 million in 2025, then slumped by 184.32% to -$36.0 million in 2026.
• Per Business Quant, the three latest VRDN Net Cash Flow figures stand at -$36.0 million (Q1 2026), $42.7 million (Q4 2025), and $52.3 million (Q3 2025).